Protalix Biotherapeutics, INC

Protalix BioTherapeutics announces significant revenue growth and profitability for Q2 2026, driven by Elfabrio sales and a milestone payment, while advancing its PRX-115 clinical trial.

Protalix BioTherapeutics stockholders elected eight directors and approved an increase in shares for the 2006 Stock Incentive Plan.

Protalix BioTherapeutics posted a corporate presentation on May 21, 2026, highlighting regulatory milestones, pipeline advancements, and financial strength.

Protalix BioTherapeutics reported strong Q1 2026 results, driven by a $25 million milestone payment from Chiesi for Elfabrio, and reaffirmed its full-year revenue guidance.

Protalix BioTherapeutics announced a positive CHMP opinion for Elfabrio's expanded dosing in the EU and provided updates on its rare disease pipeline and financial outlook.

Protalix BioTherapeutics and Chiesi Global Rare Diseases received a positive CHMP opinion for an every-four-week dosing regimen of Elfabrio for Fabry disease in the EU, potentially reducing patient burden.

Protalix BioTherapeutics announces a significant surge in revenue and net income for the second quarter of 2026, driven by strong sales of Elfabrio and Elelyso.

Protalix BioTherapeutics reports a significant increase in total revenue for Q1 2026, driven by license and R&D services, alongside a substantial improvement in operating income.

Protalix BioTherapeutics reported a net income of $2.355 million for Q3 2025, driven by increased sales to Fiocruz and R&D services, while advancing its PRX-115 gout treatment to Phase 2 clinical trials.

Protalix BioTherapeutics reports significant revenue growth driven by Elfabrio sales and reduced net loss, while advancing its pipeline and securing additional capital.

Protalix BioTherapeutics reports a significant revenue increase of 170% in Q1 2025, driven by higher sales of Elelyso and progress in its clinical pipeline.

Protalix BioTherapeutics reports a mixed third quarter with increased product sales offset by a decrease in R&D revenue, while highlighting the full repayment of convertible notes and progress in clinical trials.

Protalix BioTherapeutics reported its financial results for the fiscal year ended December 31, 2025, highlighting a net loss and increased R&D expenses while advancing its rare disease pipeline and securing a new Elfabrio dosing approval in the EU.

Protalix BioTherapeutics reports a profitable 2024 driven by Elfabrio and Elelyso sales, while advancing its pipeline with PRX-115 and PRX-119.

Protalix BioTherapeutics' 10-K filing outlines the company's capital structure, stock rights, and regulatory environment, including details on its common and preferred stock, and anti-takeover provisions.

Protalix BioTherapeutics' President and CEO, Dror Bashan, acquired 56,000 shares of common stock at $1.81 per share, increasing his direct beneficial ownership.

Protalix BioTherapeutics Director Amos Bar-Shalev sold 168 shares of common stock at $1.87 per share under a Rule 10b5-1 plan.

Protalix BioTherapeutics Director Eliot Forster acquired 7,500 restricted common shares and 15,000 stock options.

Protalix BioTherapeutics Director Gwen A. Melincoff received an award of 7,500 restricted common shares and 15,000 stock options.

Protalix BioTherapeutics director Pol F. Boudes received 7,500 restricted shares and 15,000 stock options as equity compensation.

Protalix BioTherapeutics Director Christian Elze was awarded 7,500 restricted common shares and 15,000 stock options under the company's incentive plan.

Protalix BioTherapeutics is holding its 2025 Annual Meeting of Stockholders on June 26, 2025, to vote on director elections, executive compensation, and the ratification of its independent auditor.

Protalix BioTherapeutics has changed the location of its 2024 Annual Meeting of Stockholders, while the date and time remain the same.

Protalix BioTherapeutics is holding its 2024 Annual Meeting of Stockholders to vote on the election of directors, executive compensation, amendments to the stock incentive plan, and the ratification of its independent accounting firm.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly reported a 5.8% beneficial ownership stake in Protalix BioTherapeutics, Inc.